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Abstract
Diabetes mellitus (DM) is an endocrine disorder that affects the metabolism of glucose, for
which there were an estimated 415 million cases world-wide. There are two common types of
DM, Type 1 and Type 2. A significant difference between the two types of DM is the underlying
cause of the disease but the two disease processes have similar characteristics. Both Type 1 and
Type 2 DM can be associated with severe complications. Diabetic ketoacidosis (DKA) and
hyperosmolar hyperglycemic state (HHS) are two of the most common medical emergencies.
DKA is commonly found in those with Type 1 DM and can be characterized by elevated serum
glucose levels, decreased serum pH, and the presence of ketones the serum and urine. HHS is
more commonly found in those with Type 2 DM and can be characterized by serum glucose
levels > 600 mg/dl and serum osmolality > 320 mOsm/kg. Ketones and severe metabolic
acidosis are not typically present with HHS. While there are some differences among the two
types of complications, the management of DKA and HHS are similar. Major components of
management of both conditions includes intravenous fluid resuscitation, electrolyte replacement,
and insulin therapy to manage serum glucose levels. Order sets are often used in medicine and in
other industries to guide treatment or processes. A comprehensive literature review was
conducted to examine the effectiveness of order sets in the treatment of DKA and HHS. Despite
a lack of high-level evidence, outcomes showed consistent improvements in patient outcomes
status post the implementation of a treatment guided order set. Common outcomes measured
included hospital length of stay, intensive care unit length of stay, time to anion gap closure,
hypoglycemic events, time to ketone clearance, and compliance with treatment guidelines. The
outcomes of focus of this literature review were the hospital and intensive care unit length of stay
and time to closure of the anion gap. Since the use of order sets for the treatment of DKA and
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HHS has been shown to improve patient outcomes, hospitals and hospital groups should work to
implement order sets for the treatment of hyperglycemic emergencies.
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Introduction
Diabetes mellitus (DM) is a common endocrine disorder which affects individuals of all
ages. With lifestyle changes and pharmacologic interventions, many individuals are able to
properly manage their DM but there are a number of potential acute and/or chronic
complications that can be associated with DM.
There are different categories of DM. Most individuals with DM can be classified as
having either Type 1 DM or Type 2 DM. Type 1 DM is usually the result of an inability of the
body to produce insulin. In Type 2 DM the body can produce enough insulin, but the mechanism
of sensing insulin is defective. For both types the main manifestation of the disease is an
elevation of serum blood glucose levels. Goals for management of both Type 1 and Type 2 DM
include maintaining preprandial serum glucose levels between 80-130 mg/dl. Long-term glucose
control of blood sugar levels can be assessed by measuring the hemoglobin A1c. Hemoglobin
A1c levels of less than 7% is the target goal for those with well controlled DM. (Glycemic
Targets, 2020)
The goals of management of both Type 1 and Type 2 DM are similar, but there are
differences in the pharmacological approach to achieving these goals. Since those with Type 1
DM are unable to produce insulin, the only viable means of controlling serum blood glucose
levels is to provide supplemental exogenous insulin (Pharmacologic Approaches, 2020).
Management of Type 2 DM may involve providing supplemental exogenous insulin as well as
oral hypoglycemic agents (Pharmacologic Approaches, 2010). The oral hypoglycemic agents
have a variety of mechanisms including decreasing hepatic glucose production, decreasing
absorption of glucose by the gastrointestinal tract, increasing insulin production, increasing renal
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glucose excretion, and decreasing the level of insulin resistance (Pharmacologic Approaches,
2010; Powers et al., 2018)
Among the most severe, acute complications of DM are diabetic ketoacidosis (DKA) and
hyperosmolar hyperglycemia (HHS). Treatment protocols have been developed for these medical
conditions which were established by the American Diabetes Association (ADA) in 2009
(Kitabchi, Umpierrez, Miles, & Fisher, 2009). Treatment recommendations for DKA and HHS
can be complicated as interventions include frequent laboratory sampling, hemodynamic
monitoring, and adjustment of many parameters including fluid balance, insulin, pH, glucose,
potassium, chloride, sodium, anion gap, bicarbonate, Blood Urea Nitrogen (BUN), creatinine,
serum and urine ketones, and serum osmolality (Kitabchi et al., 2009). The complexity of
treatment of DKA and HHS along with the presence of clear, evidence-based clinical guidelines
makes management of these medical conditions well-suited for use of a well-developed order set
to guide treatment. Order sets are standardized protocols that outline the care of specific disease
processes and provide guidance for the healthcare provider as to how to proceed as the disease
process progresses. Order sets can be specific to the medical institution but not every medical
institution utilizes such forms of guidance which can cause healthcare providers to make an error
in the treatment plans. Also, order sets should be developed based on evidence-based guidelines,
thus ensuring that healthcare providers are providing the most up to date, evidence-based care to
their patients. Order sets differ from clinical practice guidelines as these are developed processes
of care based on a disease process which are built off of evidence-based guidelines.
Order sets, or their equivalents (checklists, protocols, etc.), are used in a diverse variety
of industries including aviation, nuclear power, and medicine (Chan et al, 2012). Order sets in
the medical industry are typically used to guide the treatment of a particular diagnosis. For the
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diagnosis to have a well-developed order set, it is typically a diagnosis that has evidence-based
protocols that are commonly followed universally in clinical practice (pending the patients
and/or their clinical status). Unfortunately, high quality evidence including randomized
controlled trials is lacking in the support of the use of order sets for the treatment of DKA and
HHS. Studies analyzing effectiveness of previously implemented order sets typically takes the
form of retrospective chart reviews. Results of these types of studies focused on the outcomes of
individuals with DKA and HHS (Beik, Anger, Forni, Bawa, & Szumita, 2013; Bull, Douglas,
Foster, & Albert, 2007; Clark, Kraut, Yen, Moore, Hopman, & Houlden, 2019; Defayette, Voigt,
Zammit, Nadler, & Kersten, 2019; Hara, Rahbar, Jeffres, & Izuora, 2013; Joyner Blair,
Hamilton, & Spurlock, 2018; Laliberte, Yeung, & Gonzales, 2017; Maghrabi et al., 2012;
Mohamed et al., 2019). Common outcomes that were reviewed included length of hospital stay,
length of stay in the intensive care unit (ICU) as well as laboratory parameters including anion
gap closure (below 12 mEq/l), time to serum glucose normalization (< 200 mg/dl) (Kitabchi,
2009), time to bicarbonate normalization (> 15 mEq/l) (Hara, 2013) and number of
hypoglycemic events. Patient outcomes prior to order set implementation would be compared to
the same patient outcomes observed after implementation of an order set intervention,
specifically order sets to treat DKA and HHS.
In 2016 there were about 203,000 hospital admissions for DKA and another 21,000 for
HHS (Centers for Disease Control and Prevention [CDC], 2020). In 2014, the average cost of a
hospitalization for DKA was $26,566 per admission which has increased, after adjusting for
inflation, from $18,987 in 2003 and the average length of that stay decreased from 3.64 days in
2003 to 3.24 days in 2014. The total cost for hospitalizations related to DKA in the United States
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in 2014 was $5.1 billion. The average length of hospital stay was 3.24 days (Desai, Mehta,
Mathias, Menon, & Schubart, 2018).
While the evidence is generally level IV (Ackley, Swan, Ladwig, & Tucker, 2008), the
results remain consistent. Studies identified for this literature review showed a reduction in
intensive care unit length of stay and time to closure of the anion gap after the introduction of an
order set for treatment of DKA and HHS (Beik et al., 2013; Bull et al., 2007; Clark et al., 2019;
Defayette et al., 2019; Hara et al., 2013; Joyner Blair et al., 2018; Laliberte et al., 2017;
Maghrabi et al., 2012; Mohamed et al., 2019). These same studies showed improvements in
patient outcomes such as a reduction in length of hospital stay and reduction in time to glucose
normalization. Additionally, these studies showed a reduction in the number of hypoglycemic
events; a very important safety consideration since hypoglycemia has been linked to higher
inpatient mortality and poor long-term outcomes. Each day with hypoglycemia correlates to an
85.3% increase in the odds of death as an inpatient, p = .009, and a 65.8% increase in the odds of
death within one year of hospital discharge, p = .0003. They also showed hospital LOS increased
by 2.5 days for each day with a hypoglycemic event, p < .0001.
With clinical practice constantly changing with new up to date, evidence-based
information being developed, it can be difficult for healthcare providers to stay up to date with
the many clinical practice guidelines and recommendations needed to care for an array of
patients. This is particularly true for infrequently seen disease processes, especially those with
complicated monitoring, treatment plans, and interventions. Order sets can be a useful and
relevant tool to guide treatment of specific medical diagnoses based on evidence-based
interventions with a goal of continued improved patient outcomes.
Background

5

Diabetes Mellitus
DM is a chronic condition that affects individuals, without regard to ethnicity. Worldwide
prevalence of all types of DM is on the rise with an estimated 30 million cases of DM reported in
1985 increasing significantly to 415 million cases in 2017 (Powers, Niswender, & Evans-Molina,
2018). DM is a metabolic disorder for which the diagnosis is established due to hyperglycemia
and/or an elevated Hemoglobin A1c. There are at least three distinct types of DM: Type 1, Type
2, and gestational diabetes. Gestational diabetes is a complication of pregnancy and will not be
covered within this paper.
Type I DM. Type 1 DM is the result of an autoimmune disorder that results in the
destruction of pancreatic beta cells and leads to an insulin deficiency. Type 1 DM is commonly
seen in children and young adults; typically presenting before age 30 but can develop at virtually
any age (Powers et al., 2018). The autoimmune process is triggered by some type of
physiological stress. The exact nature and mechanism of the trigger is poorly understood but
could be environmental or infectious in nature. Regardless of the type of trigger, there is a
stimulation in the production of antibodies against the individual’s own pancreatic beta cells thus
facilitating the destruction of beta cells (Powers, et al., 2018). Studies have shown that Type 1
DM is associated with environmental, genetic, and immunologic factors. While genetics may
play an important role, it is not the only causative factor. Between 40-60% of identical twin pairs
found that both siblings develop Type 1 DM. This relatively low correspondence between
genetically identical pairs suggests there are factors other than genetics that play a major role in
the development of Type 1 DM (Powers, et al., 2018).
The destruction of the beta cells is a gradual process and the corresponding decline in
insulin production takes place over several years. Autopsy studies have shown clinical diabetes is
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not present until up to 70-80% of the beta cells have been lost. Prior to reaching this level of
cellular destruction, the remaining beta cells are able to compensate with higher levels of insulin
production. The transition to clinical diabetes is often precipitated by an event that usually
requires increased insulin such as an infection or puberty. In the presence of beta cell loss and
increased insulin requirements, the remaining beta cells are unable to produce enough insulin to
maintain normal blood glucose levels. This results in hyperglycemia and the onset of clinical
diabetes (Powers, et al., 2018).
Type 2 DM. Type 2 DM commonly presents later in life and appears to be more strongly
associated with genetics as compared to Type 1 DM. Studies of identical twins have shown that
Type 2 DM appears in 70-90% of both twins when found initially in one of the twins.
Additionally, if both parents have Type 2 DM, there is a 40% chance their offspring will develop
Type 2 DM (Powers, et al., 2018). The inheritance of Type 2 DM, however, is complex and may
involve multiple genes including defects in the insulin gene, the insulin receptors, and others
(McCarthy & Menzel, 2001).
Type 2 DM can manifest in one of at least three forms: insulin resistance, diminished
insulin secretion, or increased hepatic glucose production (Powers, et al., 2018). Insulin
resistance in Type 2 DM is simply the result of the inability of normal cell receptors to respond
to insulin production. The exact nature of the molecular mechanism that results in systemic
insulin resistance is not completely understood. Nevertheless, the body initially compensates for
the defective insulin response by producing more insulin. Eventually, the body is no longer able
to compensate, and, in fact, the level of insulin secretion decreases. Once Type 2 DM is
diagnosed, pancreatic beta-cell production has already reduced by as much as 50%. Again, the
exact mechanism whereby the beta-cells begin to underproduce insulin is poorly understood. An
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additional consequence of insulin resistance is related to the inability of hepatic cells to suppress
gluconeogenesis. This leads to overproduction of glucose by the liver, fasting hyperglycemia,
and decreased postprandial glycogen storage (Powers, et al., 2018).
Disorders of Hyperglycemia
DM is a disease process which has known chronic complications including retinopathy,
neuropathy, visual changes, nephropathy, and cardiovascular disease. There are two common,
severe acute complications of diabetes: Diabetic Ketoacidosis (DKA) and Hyperosmolar
Hyperglycemia (HHS). DKA more commonly presents in Type 1 DM and HHS more commonly
presents in Type 2 DM although both DKA and HHS may be seen in either Type 1 DM or Type
2 DM (Ramakrishnan & Shill, 2018; Whitlatch, Gaddam, & Ferri, 2018). About 224,000 patients
were hospitalized for a hyperglycemic crisis in 2016 with 203,000 being admitted with DKA and
21,000 being admitted with HHS (CDC, 2020). The overall rate of DKA hospitalizations among
all people is 8.8 per 1,000 people as of 2016. The overall rate for hospitalization for any diabetic
crisis is 9.7 per 1,000 (CDC, 2020). The overall incidence of HHS is more difficult to quantify
due to the lack of definitive studies. It is estimated that HHS accounts for about 1% of hospital
admissions related to DM (Corwell, Knight, Olivieri, & Willis, 2014). In 2016, there were 16
million hospital discharges with Diabetes Mellitus listed as a discharge diagnosis.
As mentioned previously, the incidence of DM is rising thus there has been an increase in
the incidence of both DKA and HHS in recent years. Despite the recent increase, DKA rates
actually decreased by about 1.1% each year from 2000-2009. This reduction is not fully
understood but could be a result of decreasing rates of DKA among younger individuals
diagnosed with Type 1 DM and the fact that DKA more commonly affects individuals under age
45 (Benoit, Zhang, Geiss, Gregg, & Albright, 2018). From 2009-2014, the overall rate of DKA
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increased for reasons that are not fully understood but could be the result of lower thresholds for
hospitalizations and/or medications that may increase the risk of DKA. (Benoit et al., 2018).
DKA mortality ranges from 1% to 5% in the adult and elderly populations respectively. Those
with significant comorbid conditions including immunosuppressed state, previous myocardial
infarction, chronic obstructive pulmonary disease, cirrhosis, heart failure, and/or previous stroke
have an increased mortality rate (Lenahan, & Holloway, 2015; Efstathiou et al., 2002). The
mortality rate associated with HHS is 10%-20%, which is much higher than that of patients with
DKA (Lenahan, & Holloway, 2015). Severe dehydration, advanced age at presentation with
HHS, and increased risk for comorbid conditions are common reasons for which HHS holds a
higher mortality rate. (Gosmanov, Gosmanova, & Kitabchi, 2018).
In addition to the reasons above, both DKA and HHS can be precipitated by other
etiologies including infection, medication non-compliance (insulin and oral hypoglycemics),
myocardial infarction, stroke, medications associated with an elevated serum glucose
(corticosteroids, beta-blockers, calcium channel blockers, and interferon alpha), trauma,
dehydration, renal failure, hypokalemia, and eating disorders (Yared & Chiasson, 2003).
Diabetic Ketoacidosis
Pathophysiology of DKA. Insulin plays several roles in the body. At low concentrations,
insulin inhibits lipolysis and shuts down ketone production. At higher concentrations, insulin
stimulates glucose uptake into cells, inhibits glycogenolysis, and stimulates glycogen synthesis
to store excess glucose (Dhatariya, 2019).
When there is insulin deficiency, there is an increase in the activity of hormone sensitive
lipase which results in higher levels of fatty acid breakdown and free fatty acid release. The free
fatty acids form acetyl-CoA via the beta oxidation pathway. The acetyl-CoA then feeds into the
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tricarboxylic acid (TCA) cycle. When free fatty acids are high, as with insulin deficiency, the
TCA cycle becomes overwhelmed and acetyl-CoA is converted into ketone bodies (which in
reality are hydroxyl acids but are commonly referred to as ketone bodies) (Dhatariya, 2019).
In the setting of DKA, the accumulation of ketone bodies (anions) leads to an open or
high anion gap and a reduction in the serum pH. The end result is a state of metabolic acidosis If
DKA is not the top differential diagnosis, then other clinical conditions should be considered that
can cause a high anion gap which could include methanol or ethylene glycol ingestion, lactate or
5-oxoproline accumulation, aspirin overdose, rhabdomyolysis, renal failure, and ketoacidosis
from other causes such as liver failure (Dhatariya, 2019).
Diagnostic criteria. The diagnostic criteria for DKA are shown in Appendix A
Table 1. There are three classifications of DKA: mild, moderate, and severe. The one
consistent criterion at all three stages is the presence of excess ketones; which can be seen in
both blood and urine. Bicarbonate and pH levels decrease with increasing severity of disease
which can lead to a worsening state of acidosis. While there is a diagnostic criterion regarding
serum glucose concentration or DKA, glucose levels are quite modest when compared to the
diagnostic criterion for HHS.
Hyperosmolar Hyperglycemic State
Pathophysiology of HHS. The pathophysiology of HHS and DKA are similar, but there
are several key differences. In HHS, insulin deficiency leads to an increase in glucagon,
catecholamines, and cortisol. The increase in these compounds leads to a corresponding increase
in both glycogenolysis and gluconeogenesis. Hypercortisolemia results in an increase in
proteolysis leading to an increase in precursors to feed gluconeogenesis. The increase in glucose
production is coupled with a decrease in glucose uptake by peripheral tissues due to low insulin
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levels and high levels of catecholamines. The combination of increased production of glucose
and decreased glucose uptake results in hyperglycemia.
In HHS, hyperglycemia initially results in osmotic diuresis and high urine output.
Diuresis eventually leads to dehydration and decreased renal perfusion. Decreased renal
perfusion affects the kidney’s ability to clear glucose effectively in the urine which leads to
higher levels of serum glucose.
Both DKA and HHS are characterized by high levels of serum glucose, however, HHS is
not associated with the production of serum or urine ketones nor is it associated with a low pH as
seen in DKA. The absence of ketones in HHS is thought to be the result of higher levels of
circulating insulin than seen in DKA, which prevents ketogenesis. Additionally, hyperosmolarity
in HHS has been shown to prevent lipolysis and the release of free fatty acids (Chiasson et al.,
2003; Pasquel & Umpierrez, 2014; Yared & Chiasson, 2003).
Diagnostic criteria. Diagnostic criteria for HHS are noted in Table 2, however, there is
only one set of diagnostic criteria as compared to the three levels of criteria noted for DKA. One
important differentiation between DKA and HHS is the significant difference in the serum
glucose levels. HHS has a significantly higher serum glucose level, which can be expected to be
over 600mg/dL whereas serum glucose levels with DKA are greater than 250mg/dL.
Additionally, effective serum osmolality is significantly elevated in HHS whereas it may or may
not be elevated in DKA. As noted, one other major difference between the two diagnoses is the
absence of serum and urine ketones with HHS.
Clinical Presentation
Physical exam. Clinical exam findings associated with DKA and HHS are similar.
Classical subjective symptoms include polyuria, polydipsia, weight loss, nausea, vomiting,
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dehydration, weakness and altered mental status. Physical exam or objective findings may
include those typically associated with dehydration such as poor skin turgor, tachycardia, and
hypotension. Both HHS and DKA can be associated with altered mental status although it is
more commonly seen in patients with HHS. Decreased mental status can be noticed along with
focal neurological signs (hemianopia and hemiparesis) and seizures (Kitabchi et al., 2009).
Those with DKA may also exhibit signs of Kussmaul respirations which is a deep and labored
breathing pattern, commonly seen with metabolic acidosis. Those with DKA also have a “sweet”
smell to their breath, comparable to that of acetic acid. Clinically, HHS has a much longer onset
which is days to weeks as compared to DKA for which the onset is hours to days. (Steenkamp,
Alexanian, & McDonnell, 2013).
Approximately 25% of patients with DKA have hematemesis for which endoscopy
results are typically positive for hemorrhagic gastritis. While abdominal pain is common in
DKA, this vague symptom can also be a symptom of a precipitating cause. If abdominal pain
does not resolve after rehydration and resolution of metabolic acidosis, further work up should
be initiated (Steenkamp, Alexanian, & McDonnell, 2013).
Even though infection is a common triggering cause for both HHS and DKA, patients
often present normothermic or even hypothermic. Peripheral vasodilation can contribute to heat
loss and severe hypothermia as an indicator of a poor prognosis (Kitabchi et al., 2009).
A majority of DKA and HHS cases have some precipitating factor although in 20-30% of
DKA and HHS cases, no precipitating factor can be determined. Infection and discontinuation of
insulin and oral hypoglycemic agents are the most common triggers for DKA and HHS events.
Infection is thought to be the cause for 40-60% of cases of HHS. Pneumonia and urinary tract
infections are among the most common infections noted in the literature. Additional medical
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conditions such as stroke, myocardial infarction, and trauma may contribute to HHS by altering
hormone levels or by reducing access to water. (Morgan & Kaufman, 2019)
Laboratory studies. The diagnostic criteria for DKA and HHS are listed in Appendix A
Table 1 and Table 2. Both tables show common laboratory values seen in patients with
DKA and HHS. Similar to the diagnostic criteria, glucose levels commonly seen in HHS are
much higher than in DKA. Bicarbonate, pH, and total osmolality are all significantly higher in
HHS compared to DKA while anion gap is much higher in DKA. Additionally, 3-ßhydroxybutyrate levels are negligible in HHS but elevated with DKA.
Medical Management of Diabetic Emergencies
There are three main common components to the treatment of DKA and HHS. These
common treatment methods include intravenous fluid resuscitation, electrolyte replacement, and
control of serum glucose levels with exogenous insulin. While the treatment recommendations
for HHS and DKA are similar, the protocols will be discussed separately to help illustrate the
subtle differences.
DKA management.
Intravenous fluids. Normal saline is recommended as the intravenous fluid (IV) of
choice for initial fluid resuscitation. In the first hour of treatment, 1000-1500 milliliters (mL) of
Normal Saline should be administered. After the initial fluid bolus, the fluid rate should be
between 250-500 ml/hour (Karslioglu French et al., 2019). The fluid choice and rate should be
adjusted based on the electrolyte values and hemodynamic status of the patient. For example,
patients with normal or high sodium levels should be transitioned to 0.45% saline rather than
0.9% saline after the initial fluid bolus (Karslioglu French et al., 2019). As patients’
hemodynamic status stabilized and electrolyte values approach normal levels, the rate of IV fluid
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administration can be decreased. There are no specific randomized controlled trials that give
specific guidance as to the optimal fluid rate, thus the decision is left to the individual provider
(Karslioglu French et al., 2019). Throughout initial fluid resuscitation, continued use of normal
saline may lead to hyperchloremic metabolic acidosis. The kidneys compensate for the high
levels of negatively charged chloride ions in the serum by driving down the levels of the
negatively charged bicarbonate ions. This results in an artificially low bicarbonate level leading
to metabolic acidosis that does not respond appropriately to the DKA treatment (Marino, 2014).
DKA treatment carries a high risk of the development of hypoglycemia. To prevent
episodes of hypoglycemia, when blood glucose levels are < 200mg/dL, IV fluids should be
continued but with the addition 5% Dextrose to prevent hypoglycemic episodes (Karslioglu
French et al., 2019).
Electrolytes. Those individuals with adequate renal function and present with
hypokalemia should have potassium replacement provided. When serum potassium is less than
5.2 mEq/l, resuscitation fluid with 20-30 mEq of potassium chloride should be used. Insulin
initiation will cause an intracellular shift of potassium which results in lower readings of
potassium. Thus, potassium supplementation is implemented even when serum levels are on the
upper limit of normal. An additional consideration of the intracellular shift of potassium is that
insulin therapy should be held until the serum potassium level is over 3 mEq/L; thus preventing
worsening hypokalemia. Routine replacement of bicarbonate and phosphorus is not currently
recommended (Karslioglu French et al, 2019). Electrolytes, BUN, venous pH, creatinine, and
glucose should be checked at least every two to four hours until the values are normalized
(Kitabchi et al., 2009).
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Insulin. As mentioned previously, insulin therapy should not be initiated until serum
potassium is above 3 mEq/L. Insulin should be started at either a higher fixed weight-based dose
of 0.14 units/kilogram(kg)/hr or at a fixed weight-based dose of 0.1 units/kg/hr with a bolus of
0.1 units/kg. If the blood glucose level does not decrease by 50-75 mg/dL in the first hour,
insulin dosage should be increased but the ADA does not give specific guidance regarding the
exact quantity of the insulin increase. Point of care blood glucose monitoring should occur every
hour and insulin adjusted every hour until a steady decline in the blood glucose level is observed.
When the blood glucose level is below 200 mg/dL, insulin should be titrated to keep the blood
glucose level between 150-200 mg/dL and 5% Dextrose should be added to the IV fluids to
prevent hypoglycemia (Karslioglu French et al., 2019).
Kitabchi et al. (2009) state the transition to subcutaneous insulin should not be done until
the hyperglycemic crisis has resolved. Resolution of DKA includes a serum blood glucose less
than 200 mg/dl and at least two of the following criteria: serum bicarbonate ³ 15 mEq/l, venous
pH > 7.3, and anion gap £ 12 mEq/l.
HHS management
Intravenous fluids. The initial fluid resuscitation recommendations for HHS and DKA
are identical. The current recommendations for HHS include 1000 mL of normal saline within
the first hour of treatment. As with DKA, there is the recommendation to add 5% Dextrose to IV
fluids once the blood glucose level drops below 300 mg/dL to prevent hypoglycemia. The reason
for this blood glucose level to be used as a reference point is not well understood (Karslioglu
French et al, 2019).
Electrolytes. The recommendations for potassium replacement are the same in HHS and
DKA. This includes holding insulin therapy until the serum potassium level is at least 3 mEq/L
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to prevent worsening hypokalemia and including potassium in the resuscitation fluid when
potassium is less than 5.2 mEq/l (Karslioglu French et al., 2019). Electrolyte levels should be
checked with the same frequency as in DKA (at least every two to four hours until the values
become stable) (Kitabchi et al., 2009).
Phosphorus replacement is generally not recommended. Studies have shown no
improvement in outcomes as a result of phosphorus replacement (Kitabchi et al., 2009).
Additionally, aggressive phosphorus replacement can cause hypocalcemia (Kitabchi et al., 2009).
In patients with cardiac dysfunction, anemia, respiratory depression or when serum phosphorus
is below 1.0 mg/dl, phosphate may be replaced slowly. Phosphate should be replaced at a rate of
4.5 mmol/hr (Kitabchi et al., 2009).
Similarly, the replacement of bicarbonate is generally not recommended unless acidosis
is severe. If the pH is less than 6.9, patients should be given 100 mMol sodium bicarbonate with
20 mEq KCl. The bicarbonate/potassium solution should be given over two hours. If the pH is
still less than 7.0, this infusion should be repeated every two hours until the pH is over 7.0. There
are no specific randomized studies to support this recommendation. However, it is known that
severe acidosis can lead to adverse vascular effects (Kitabchi, 2009).
Insulin. The ideal time to initiate insulin therapy has not been determined for those in a
state of HHS. Current recommendations state that insulin therapy is to be started after initial fluid
resuscitation and correction of hypokalemia. As with timing, the optimal insulin dosing for HHS
has not been determined. The current recommendations are to start insulin at the same level as
with DKA (a fixed weight-based dose of 0.14 units/kg/hr with no bolus or fixed weight-based
dose of 0.1 units/kg/hr preceded by a bolus of 0.1 units/kg). Blood glucose levels should be
monitored every hour as with DKA, and insulin should be increased until the level drops by
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about 50-75 mg/dL per hour. When the blood glucose level is below 300 mg/dL, insulin level
should be titrated to keep blood glucose levels between 250-300 mg/dL (Karslioglu French et al.,
2019).
As with DKA, transition to subcutaneous insulin should not be done until the resolution
of the hyperglycemic crisis. HHS is thought to be resolved when the serum blood glucose has
returned to normal levels (< 200 mg/dl), serum osmolality is normal (285-295 mOsm/kg H2O),
and return to normal mental status (Kitabchi, 2009).
Order Sets
“Order sets are groups of medical orders that work to standardize diagnosis and treatment
following pre-established clinical guidelines or protocols” (Chan et al., 2012, p. 235). Most order
sets include orders for medications and therapies for specific situations (e.g., general admission,
ICU admission, post-operative, etc.) or for specific conditions (e.g., diabetes, DKA, asthma, etc.)
(Chan et al., 2012).
Order sets are used in a variety of diverse industries from healthcare to aviation to
nuclear power and are considered an important safety measure (Chan et al., 2012). Studies have
shown adherence to clinical guidelines helps to improve patient outcomes (Fowkes et al., 2010).
Research into order sets has shown they help to increase adherence to guidelines (Fowkes et al.,
2010; Walker et al., 2011) and they also help to improve patient outcomes. Order sets have also
been shown to consistently reduce consumption of healthcare resources including supplies,
medications, provider time, and money (Rivers, Coba, & Rudis, 2009).
Unfortunately, the benefits of order sets are difficult to study using a truly randomized or
blinded study design. The body of order set research in the healthcare industry is generally low
quality (Chan et al., 2012). The main reason for this is the difficulty of setting up truly
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randomized controlled trials. One important component of order set implementation is education
of the staff who will be using the order set. In this type of setting, it would be impossible to
determine if changes in patient outcomes were due to the order set or simply from knowledge of
the order set (Chan et al., 2012).
An example of an order set used to treat DKA and HHS can be seen in Appendix C. The
order set was adapted from Bull et al. (2007) and is used with permission. The order set does not
follow the ADA recommendations precisely. For example, the insulin dosing is not weightbased. Nevertheless, this order set does contain guidance regarding monitoring and
administration of IV fluids, electrolytes, and insulin.
Purpose
Treatment protocols and recommendations for DKA and HHS are well-established by the
American Diabetes Association (ADA) (Karslioglu French et al., 2019). While the protocols are
well-established, implementation of these protocols can be inconsistent. Noncompliance with the
recommended protocols can result in less than ideal management of DKA and HHS including
delayed IV fluid resuscitation and delayed initiation of IV insulin therapy. Consequently, these
delays can result in increased hospital length of stay including time spent in the ICU and overall
poor patient outcomes.
The analysis of compliance with the ADA’s DKA and HHS recommendations is limited.
A chart review conducted at an academic medical center’s medical intensive care unit (MICU)
showed that only 20% of the patients with DKA in the MICU were treated according to the most
recent ADA recommendations for fluid resuscitation and initiation of insulin (Fusco, Gonzales,
& Yeung, 2015). There were no statistical differences in the observed outcomes, but the authors
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maintain the trends indicate protocol compliance will improve outcomes. Unfortunately, the
authors of the study did not investigate the reason for non-compliance with the guidelines.
Order sets are generally used to guide and manage treatment for an array of medical
situations (admission, various procedures) or to manage specific medical conditions (asthma,
diabetes). Management of patients using order sets based on existing clinical guidelines has been
thought to improve patient outcomes. Chan et al. (2012) conducted a systematic review of the
use of order sets and concluded order sets “could positively influence guideline adherence,
treatment outcomes, processes of care, efficiency, and cost” (Chan et al., 2012, p. 238).
The purpose of this literature review is to investigate the effectiveness of order sets in the
treatment of DKA and HHS to improve patient outcomes.
Research Question Guiding Purpose
A clinical question was developed to guide the literature review. The clinical question is
as follows: In hospitalized patients with DKA, HHS, or hyperglycemia, does using a
standardized protocol or order set compared to provider preference (physician, advanced practice
provider, or pharmacist) improve overall patient outcomes during the hospital stay? Specific
outcomes include length of ICU stay and time to anion gap closure.
Method of Inquiry and EBP Model
The Iowa Model of Evidence-Based Practice (Iowa Model) is commonly used as a
scheme for integration of research into nursing practice. The model outlines a stepwise approach
to implementing a practice change. The steps have several critical decision points where the
project is assessed and, depending on the assessment, the project is either moved forward,
reworked to better fit the needs of the organization, or dropped altogether. The project could be
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dropped because it no longer fits the needs of the organization or because it has become clear the
project is not feasible.
This review covers the first four steps and the first decision point of the Iowa Model as
depicted in Figure 1. The bulk of the work for this review was in step four: “assemble, appraise,
and synthesize body of evidence.” The model breaks this step into two components: “conduct a
systematic search” and “weigh quality, consistency, and risk.” The systematic search is covered
in subsequent sections along with and analysis of the body of evidence. Risk was not assessed in
this analysis. Information regarding risk was found in the literature search and should be
assessed prior to moving forward with implementation.
Aside from an analysis of the risk, this review provides an assessment of the available
literature and a recommendation regarding the utility of order sets for the treatment of DKA and
HHS. This review answers the question at the second decision point: “is there sufficient
evidence?” This study does not address the final three steps of the Iowa Model, nor does it
address the final decision point. If this research is to be implemented, these steps and decision
points must be addressed.
Database Search
The literature search strategy is outlined in Table 4. The initial search was focused on
DKA and search terms that could be used interchangeably with DKA such as hyperglycemia or
diabetic ketoacidosis. The initial search also included the search term protocol. Some of the hits
in this search were focused on differentiating between DKA and HHS while other studies were
related to hyperglycemia in general and not hyperglycemic emergencies such as DKA and HHS.
Protocol as a search term also led to studies examining individual components of treatment plans
rather than a comprehensive treatment plan.
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Using the search term order set rather than protocol helped to narrow the search to
studies of comprehensive treatment plans rather than individual components of treatment plans.
Narrowing the search to studies published since 2010 yielded a more manageable number of hits.
Initial searches were conducted using the CINAHL database. Subsequent identical searches were
conducted using the OVID and PubMed databases. These searches yielded one and seventeen
hits respectively.
An analysis of duplicated articles left 28 hits from CINAHL, 8 hits from OVID, and 39
unique hits from Pubmed. An analysis of the abstracts and titles allowed for the elimination of a
number of articles. Many articles were eliminated due to the focus on the pediatric population.
Subsequent articles were eliminated as the focus was on treatment of hyperglycemia without
meeting the criteria for either DKA or HHS. This led to the selection of 15 articles for analysis of
the content. Review of the references of these 15 articles led to the selection of five additional
articles for further analysis. Careful review of the 20 articles allowed for the elimination of 11
for several reasons including an improper target group (pediatrics), improper setting (general
care), or improper disease state (hyperglycemia without acidosis or hyperosmolarity). Thus, the
final total number of articles analyzed in this review was nine. Throughout the process, nonsystematic reviews and expert opinion articles were eliminated when identified.
The nine articles were classified according to their level of evidence (Ackley et al.,
2008). Ackley et al. (2008) describe seven levels of evidence ranging with the most convincing
(Level I) being a systematic review or meta-analysis and the least convincing (Level VII) being
expert opinion (see Table 7). The nine papers selected all fell into Level IV. All of the studies are
analyses of separate cohorts. The study authors analyzed the outcomes of patients having
diabetic emergencies (either DKA or HHS) before implementation of an order set. The authors
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then implemented a hyperglycemia management order set including education of the providers,
nurses, pharmacists, and other staff who would be responsible for using the order set. The
authors then looked at the outcomes of patients after the order set implementation and compared
the two groups of patients (Beik et al., 2013; Bull et al., 2007; Clark et al., 2019; Defayette et al.,
2019; Hara et al., 2013; Joyner Blair et al., 2018; Laliberte et al., 2017; Maghrabi et al., 2012;
Mohamed et al., 2019). Given the study design, randomization of groups was impossible.
Literature Review
Order Sets
The literature contains numerous studies examining the implementation of order sets in
hospital environments. Unfortunately, the evidence related to order sets is consistently level IV
(Ackley et al., 2008). Most studies use simple before and after designs rather than Level II
(Ackley et al., 2008) randomized controlled trials (RCT) (Chan, et al., 2012). In fact, blinding
and randomization are required for RCT study design, but are nearly impossible in the design of
a study of order set effectiveness. It would be difficult for a healthcare provider to use an order
set for the treatment of one patient and not be influenced by the order set when treating a patient
from the non-order set group.
While the evidence regarding order sets is, generally, level IV (Ackley et al., 2008), the
results are consistent. In their systematic review of order sets in healthcare, Chan, et al. (2012)
concluded, “published studies generally suggested that order set implementation could result in
positive outcomes, processes of care, efficiency, and cost.” (p. 239) Chan et al. also conclude
that future studies would be of higher quality if they included “larger sample sizes, studies with a
concurrent controlled group, [and] studies across multiple sites.” (2012)
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Individual studies of order sets for the care of stroke (Elder, Lemon, & Costello, 2015),
sexual assault (Britton, Bloch, Strout, & Baumann, 2013), community acquired pneumonia
(Fowkes, Gee, Bluemink, Cole, Falkner, & Hamour, 2010), sepsis (Thiel et al., 2009). and endof-life care (Walker, Nachreiner, Patel, Mayo, & Kearney, 2011) have all shown improved
outcomes and/or adherence to guidelines with the implementation of order sets. These separate
studies bear the already mentioned limitations of non-randomized designs and small sample
sizes. Nevertheless, the improvements are real and measurable.
The study by Elder et al. (2015) shows improved outcomes for patients who have had a
stroke, but also improved compliance with adherence to standards. Patients who were treated
without the use of an order set were over twice as likely to be given care non-compliant with at
least one of eight quality standards, OR 2.4, 95% CI [1.43, 4.05], p < .001. Use of the order set
improved compliance with three of the standards: venous thromboembolism prophylaxis (with
order set 91.4% adherence and without order set 74% adherence, p = .01, discharged with statin
therapy (with order set 91.4% adherence and without order set 68% adherence, p = .001),
receiving stroke education (with order set 81.4% adherence and without order set 54%
adherence, p = .001), The outcomes were improved in the order set group, but statistics were not
provided.
Britton et al. (2013) showed that compliance with Centers for Disease Control and
Prevention guidelines for treatment of sexual assault victims was very low (4.4%) prior to the
implementation of a computerized order set, but increased to 82.4% after the implementation of
the order set, c2 = 291.635, df = 1, p < .001.
Fowkes et al., 2010) analyzed the use of a preprinted order set for patients admitted with
community-acquired pneumonia. In their analysis 64% of patients received treatment according
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to the guidelines established by the Infectious Diseases Society of America and the American
Thoracic Society prior to implementation of an order set and 92% of those treated with the order
set were in compliance with the guidelines, p = .012.
Thiel et al. (2009) were able to show a decrease in mortality in patients with septic shock
from 55% in the pre-order set implementation group to 39.5% in the post-order set
implementation group, p < 0.01. They were also able to show a decreased hospital LOS in the
post-order set implementation group from 28.7 days to 22.4 days, p = 0.02. In addition to the
improved outcomes, the authors were also able to demonstrate better adherence to standards in
the post implementation order set group compared to the before implementation group: average
intravenous crystalloid resuscitation 2,054 ml post group and 1,627 pre group, p = .04; 65.5%
receiving the appropriate first antibiotic in the post group compared to 53% in the pre group, p =
.01.
Finally, Walker et al. (2011) examined the use of an order set to direct end of life care.
The order set improved adherence to the institutional comfort measures guidelines. For example,
before the implementation of the order set, 40.8% of the patients had labs drawn and 3.2% had
labs drawn after implementation of the order set, p < .0001 and 9.2% were given blood products
pre order set and 0% were given blood products after the order set, p = .0233. In addition to
preventing unnecessary and unwanted interventions, the order set also improved some aspects of
treatment. Opioids were made available to 19.7% of patients in the pre order set group and 100%
of the patients in the post order set group, p = .0002, and antianxiety medications were made
available to 15.8% of the patients before the order set and 100% of the patients after
implementation of the order set, p < .0001.
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This analysis of the general applications of order sets is not exhaustive, but it is believed
to be representative. The consistency of the benefits of order sets is reflected in their use across a
wide variety of industries. Order sets, or their equivalent, are used with good results in industries
as varied as aviation and nuclear power (Chan, et al., 2012). The successful use of order sets in
various industries supports their use in general and supports their use in the health care industry.
DKA and HHS Order Sets
The literature on the use of order sets to direct the care of patients having hyperglycemic
emergencies is limited by the low level of evidence. These limitations are also present in the
evidence for the use of order sets in other health care related issues and for processes outside of
healthcare. The main limitation is the lack of randomized controlled trials. Most studies related
to order sets are of a retrospective chart review design and these studies examine patient
outcomes prior to the implementation of the order set. After implementation of the order set, the
same outcomes were measured (Beik et al., 2013; Bull et al., 2007; Clark et al., 2019; Defayette
et al., 2019; Hara et al., 2013; Joyner Blair et al., 2018; Laliberte et al., 2017; Maghrabi et al.,
2012; Mohamed et al., 2019).
The nine studies identified in this literature search give consistent support to the benefit
of using order sets to improve the outcomes of patients who are having hyperglycemic
emergencies. As with all literature reviews, this study is complicated by differences in reporting
by the nine different studies. Nevertheless, all nine studies showed at least a partial benefit to
order sets or trend in that direction including at least one of the following measurable
parameters: decreased hospital or ICU stays after the implementation of an order set, decreased
time of resolution of DKA/HHS after the implementation of an order set or decreased time to
anion gap closure after the implementation of an order set (see below for data) (Beik et al., 2013;
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Bull et al., 2007; Clark et al., 2019; Defayette et al., 2019; Hara et al., 2013; Joyner Blair et al.,
2018; Laliberte et al., 2017; Maghrabi et al., 2012; Mohamed et al., 2019).
Length of stay. Three of the nine studies in this review showed a reduction in either
hospital length of stay (LOS) or ICU LOS (Beik et al., 2013; Bull et al., 2007; Hara et al., 2013).
Two of the remaining six studies reported a trend towards a reduced hospital or ICU LOS but the
reported differences were not statistically significant: pre order set implementation 4.6 days and
post order set implementation 3.53 days (total hospital LOS), p = .102 (Clark et al., 2019); pre
order set 7.26 days and post order set 5.21 days (total hospital LOS), p = .1242 (Joyner Blair et
al., 2018). One study concluded the LOS were almost identical pre and post intervention
(Defayette et al., 2019) and two studies contained no data regarding the LOS (Maghrabi at al.,
2012 and Mohamed at al., 2019). Only one of the nine studies (Laliberte et al., 2017) showed a
non-significant increase in ICU LOS after implementation of a hyperglycemic emergency order
set.
Laliberte et al. (2017) acknowledge their results disagree with much of the literature
related to order sets although their LOS results do not meet statistical significance. Laliberte et
al. (2017) reported an increase in ICU stay from 39.8 hours pre order set to 47 hours after the
implementation of the order set, p = 0.09. Even though the increase is not statistically significant
it is notable as the trend is opposite direction compared to other studies after the implementation
of an order set. Laliberte et al. (2017) give several explanations offered for the observed increase
in ICU LOS. First, there is an acknowledgement of the small sample size as the study included
115 patients with 60 participants in the pre-order set cohort and 55 participants in the post-order
set cohort. Second, it was thought that the patients in the study had more severe disease than
those in some previous studies. The authors state many patients are treated for DKA in the
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emergency department and are never admitted to the ICU. The authors did not report these
numbers but did state that there was no difference in ICU LOS among those who were admitted
with concurrent coma, sepsis or among those who required mechanical ventilation. It was
acknowledged in the study that the severity of the illness or comorbid conditions were not
accounted for within the study (Laliberte et al., 2017).
The studies in which the data reached statistical significance reported a decrease in
hospital LOS, ICU LOS or both. For example, Beik et al. (2013) saw the mean ICU time
decrease from 64.8 hours in the pre-order set implementation group to 37.1 hours in the postorder set implementation group, p < .01. A reduction of 27.7 hours spent in the ICU. Bull et al.
(2007) found the mean ICU stay was reduced from 44 hours to 34 hours, p < .007. The mean
hospital stay was reduced from 91 hours to 64 hours, p < .007. Hara et al. (2013) report that
patients treated with the order set were in the ICU 9.20 hours less than those treated without the
order set, 95% CI [4.70, 13.70], p < .001 and when treated with the order set were in the hospital
2.04 days fewer than those treated without the order set, 95% CI [0.61, 3.46], p = .05.
Time to anion gap closure or time to resolution of the hyperglycemic emergency. Six
of the nine studies selected for this analysis showed either a significant reduction in time to anion
gap closure (Beik et al., 2013, Bull et al.; 2007, Maghrabi et al., 2013; Mohamed et al., 2019) or
a reduction in time to resolution of the hyperglycemic emergency (Hara et al., 2013; Laliberte et
al., 2017). Two of the remaining studies (Clark et al., 2019; Defayette et al., 2019) reported a
trend toward a decreased time to anion gap closure, but the differences were not statistically
significant.
The importance of anion gap as a diagnostic tool was discussed previously and the
requirements for diagnosis of DKA and HHS can be seen in Appendix A
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Table 1 and Table 2 respectively. Anion gap is simply the difference between the cations
and the anions in the serum. The anion gap is usually calculated by reviewing the major cations
in the serum (sodium and potassium) and the major anions (chloride and bicarbonate). The
typical anion gap seen in DKA and HHS are shown in Table 1and Table 2. “Anion gap closure”
refers to the return of an elevated anion gap, typically seen in DKA and sometimes seen in HHS,
to normal levels. Normal anion gaps are defined by the labs conducting the tests, but the anion
gap is usually thought to be closed when the level is below 12 mEq/l (Lenahan & Holloway,
2015)
Beik et al. (2013) report the time to anion gap closure was reduced from 13 hours in the
pre order set group to 9.3 hours in the post order set group, p < .01. Bull et al. (2007) and
Mohamed et al., (2019) also showed a decrease in time to anion gap closure: a reduction from
15.4 hours pre order set to 10.3 hours post order set, p < .001 and 10.5 hours pre order set to 6.0
hours post order set, p < .01, respectively. Finally, Maghrabi et al. (2013) showed a reduction
time to anion gap closure from 11.5 hours pre order set to 8.5 hours post order set, p = .008.
Two studies showed a significant reduction in time to DKA resolution. Laliberte et al.
(2017) define time to DKA resolution at the time from the initiation of an insulin infusion to the
time when serum glucose drops below 200 mg/dl and at least two of the three following criteria
are met: anion gap ≤ 12 mEq/l, serum bicarbonate ≥ 15 mEq/l, or venous pH > 7.3. This study
showed a reduction in time to meet these criteria from 11.1 hours to 9 hours, p = .04. Hara et al.
(2013) used the same criteria for DKA resolution (and required meeting all the criteria) but also
included the following criteria for HHS: serum glucose < 300 mg/dl and serum osmolality < 320
mOsmol/kg. Using these criteria, the authors showed a reduction in time to resolution from 22.8
hours in the pre order set group to 13.6 hours in the post order set group, p < .001.
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Two studies showed a reduction in time to anion gap closure even though the results were
not statistically significant. Defayette et al. (2019) and Clark et al. (2019) showed a reduction in
time to anion gap closure from 24.1 hours to 22.8 hours, p = .45 and 5.2 hours to 4.0 hours, p =
.09, respectively.
AGREE II Analysis of Treatment Guidelines
The order sets used in the research studies were developed using recommendations from
the ADA (Beik et al., 2013;Bull et al., 2007;Defayette et al., 2019; Hara et al., 2013; Joyner Blair
et al., 2018; Laliberte et al., 2017; Maghrabi et al., 2012) or Diabetes Canada (Clark et al., 2019;
Mohamed et al., 2019). The AGREE II (Appraisal of Guidelines for Research & Evaluation II)
tool developed by Brouwers et al. (2010) was used to analyze the two sets of recommendations.
The two sets of recommendations both had an average scores of 3.83 and 4.09 (Table 5
and Table 6). The value of the score is held down for both the ADA guideline and the Canadian
diabetes guideline by the lack of methodology in both guidelines. Neither guideline gave any
indication of the methodology used in developing the recommendations or their literature
searching strategies. The recommendations regarding the diagnosis, treatment, and prevention of
DKA and HHS were relatively strong (Table 5 and Table 6).
Literature Summary and Conclusion
The lack of carefully controlled, randomized studies is a limitation for any conclusions
that are to be drawn from the studies included in this review. The results of the studies included
in this review, however, are very consistent and are similar to the results from previous studies
examining the use of order sets to improve patient outcomes. The studies show, despite
differences in data reporting, there is a reduction in both ICU LOS and time to anion gap closure
when an order set is used to direct care for patients who have DKA or HHS (Beik et al., 2013;
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Bull et al., 2007; Clark et al., 2019; Defayette et al., 2019; Hara et al., 2013; Joyner Blair et al.,
2018; Laliberte et al., 2017; Maghrabi et al., 2012; Mohamed et al., 2019).
Conclusions
Implications for Practice
The implications relate mainly to the need to follow a planned order set when treating
conditions such as DKA and HHS. Most healthcare providers have a general idea of the
treatment outline for such conditions, but it is unrealistic to expect providers to have all treatment
plans memorized particularly for conditions seen infrequently.
Additionally, this research emphasizes the importance of following evidence-based
practice guidelines. There appears to be a clear benefit of using an order set. The reason for the
benefit may be related to the order set specifically or could be due to additional education at the
time the order set is introduced. The benefits of the order set could also be a result of heightened
awareness of the order set.
Finally, the order set can help bedside nurses to facilitate care of patients with DKA and
HHS. The order set can provide valuable guidance to nurses to help them direct care and to know
when their concerns need to be elevated the on-call provider.
Laliberte et al. (2017) showed that adherence to the guidelines before the implementation
of a defined order set was poor compared to compliance after implementation of the order set.
Overall compliance with the ADA recommendations before implementation of the order set was
31.7%. After implementation of the order set, compliance with the ADA recommendations rose
to 65.5%, p = .0004. Use of the order set appears to improve outcomes through better compliance
with the most current evidence-based recommendations.
Recommendations and Summary
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DKA and HHS are among the most serious complications of DM. DKA is most often
seen in younger people with Type 1 DM and HHS is seen most often in older patients with Type
2 DM. Both, however, can be seen at any age and in either Type 1 or Type 2 DM. The mortality
rate for DKA is about 1-5% and the mortality rate for HHS even higher, about 10-20%. The
diagnosis and treatment for both DKA and HHS are similar in terms of the guidelines and
complexity of treatment. Treatment for both conditions involves fluid resuscitation, electrolyte
replacement, and normalization of serum glucose levels. The complexity of the treatment for
DKA and HHS coupled with the seriousness of both conditions, makes them well suited for
development of an order set.
Order sets (checklists or protocols) are used in a wide variety of industries to help
standardize approaches to problems and to help ensure that complicated processes are managed
appropriately. In the medical field, order sets are used to assist healthcare providers manage
complex disease states. Order sets have been successfully and safely used to manage stroke
(Elder et al., 2015), sepsis (Thiel et al., 2009), sexual assault (Britton et al., 2013), pneumonia
(Fowkes et al., 2010), and end-of-life care (Walker et al., 2011).
The results from the research included in this review indicate order sets for the treatment
of DKA and HHS improve outcomes. This benefit is manifested by shorter time spent in the ICU
and shorter time to DKA resolution (specifically less time to anion gap closure). Consequently,
order sets provide benefits to both patients and institutions resulting in lower costs to the health
care system and reduced emotional and physical costs as a result of shorter hospitalization.
Despite this, many providers and institutions have been hesitant to implement order sets or to use
them once they have been implemented. The reasons for this hesitancy are unclear and have not
been thoroughly researched. Nevertheless. The research presented here indicates a benefit to the
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use of order sets for many conditions including DKA and HHS. Thus, it is important for
institutions to develop an order set for hyperglycemic emergencies such as DKA and HHS and to
integrate the order set into the standard of care for these disease states.
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Appendix A
Table 1 Diagnostic criteria for DKA (Kitabchi et al., 2009).
Mild

Moderate

Severe

Serum glucose (mg/dl)

>250

>250

>250

Arterial pH

7.25-7.30

7.00-7.24

<7.00

Serum bicarbonate (mEq/l)

15-18

10-15

<10

Urine ketone

Positive

Positive

Positive

Serum ketone

Positive

Positive

Positive

Anion gap

>10

>12

>12

Mental status

Alert

Alert/drowsy

Stupor/coma

Anion gap: [Na+] – ([Cl-] + [HCO-])
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Table 2 Diagnostic criteria for HHS (Kitabchi et al., 2009).
Serum glucose (mg/dl)

>600

Arterial pH

>7.30

Serum bicarbonate (mEq/l)

>18

Urine ketone

Small

Serum ketone

Small

Effective serum osmolality

>320 mOsm/kg

Anion gap

Variable

Mental Status

Alert

Effective serum osmolality: 2[measured Na+ (mEq/L)] + glucose (mg/dl)/18. Anion gap: [Na+] –
([Cl-] + [HCO-])
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Table 3 Common lab values for patients admitted with DKA or HHS
DKA

HHS

Glucose (mg/dl)

616 ± 36

930 ± 83

Na+ (mEq/l)

134 ± 1.0

149 ± 3.2

K+ (mEq/l)

4.5 ± 0.13

3.9 ± 0.2

BUN (mg/dl)

32 ± 3

61 ± 11

Creatinine (mg/dl)

1.1 ± 0.1

1.4 ± 0.1

pH

7.12 ± 0.04

7.3 ± 0.03

Bicarbonate (mEq/l)

9.4 ± 1.4

18 ± 1.1

3-ß-hydroxybutyrate

9.1 ± 0.85

1.0 ± 0.2

323 ± 2.5

380 ± 5.7

17

11

(mmol/l)
Total osmolality
(mOsm/kg H2O
Anion gap
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Table 4 Literature search strategy
Date of
Search
8/6/2019

8/6/2019

8/6/2019

8/20/2019

10/15/19

Database/Source
Keyword
Used (CINAHL,
Used
OVID, Proquest,
Google Scholar, etc.)
dka or diabetic CINAHL Complete
ketoacidosis
or
hyperglycemia
AND
protocol
dka or diabetic CINAHL Complete
ketoacidosis
or
hyperglycemia
AND
Order set
dka or diabetic CINAHL Complete
ketoacidosis
or
hyperglycemia
AND
Order set
Published
2010 or later
dka or diabetic OVID
ketoacidosis
or
hyperglycemia
AND
Order set
Published
2010 or later
dka or diabetic Pubmed
ketoacidosis
or
hyperglycemia
AND
Order set
Published in
the last 10
years

# of Hits
Listed

Reviewed

Used

660

0

40

0

28

28

6

9

9

1

53

53

6
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Table 5 AGREE II assessment of the ADA guidelines (Brouwers et al., 2010; Kitabchi et al.,
2009)
AGREE II Rating
Domain
Scope and
purpose

Stakeholder
involvement

Item

1
Strongly
Disagree

2 3 4 5 6

7
Strongly
Agree

1. The overall objective(s) of the guideline is (are)
specifically described.
Comments:
“This consensus statement will outline precipitating factors
and recommendations for the diagnosis, treatment, and
prevention of DKA and HHS in adult subjects” (p. 2739)

X

2. The health question(s) covered by the guideline is (are)
specifically described.
Comments:
The guidelines are presented to help diagnose and direct the
care of adults who are having a hyperglycemic emergency.
The guideline contains specific diagnostic criteria to
differentiate between mild, moderate, and severe DKA and to
differentiate between DKA and HHS. The guideline also
contains some specific parameters for monitoring and
treatment including fluid management, insulin therapy, and
electrolyte monitoring.

X

3. The population (patients, public, etc.) to whom the
guideline is meant to apply is specifically described.
Comment:
The guideline has been designed to help diagnose and treat
adults with either Type 1 or Type 2 DM who are having a
hyperglycemic emergency (HHS or DKA).

X

4. The guideline development group includes individuals
from all the relevant professional groups.
Comment:
This is unclear from the paper. The authors of the guideline are
all MDs. No mention was made of any stakeholders other than
the ADA.

X

5. The views and preferences of the target population
(patients, public, etc.) have been sought.
Comment:
No evidence was given of any assessment of end user needs.

X

6. The target users of the guideline are clearly defined.
Comment:

X
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AGREE II Rating
Domain

Item

1
Strongly
Disagree

2 3 4 5 6

The target users are not specifically identified, but the context
of the guideline implies the end user will be people directing
the care of patients with DKA and HHS.
Rigor of
development

7. Systematic methods were used to search for evidence.
Comment:
The paper contains no methods section outlining literature
searching strategies. The paper mentions it is based on a
previous technical review published in 2001 (Kitabchi et al.,
2001) and peer-reviewed articles published since that time.
Another article, apparently published by the same group, was
published in 2006 (Kitabchi, Umpierrez, Murphy, &
Kreisberg, 2006). Again, this article has no mention of the
literature search strategy.

X

8. The criteria for selecting the evidence are clearly
described.
Comment:
The guideline only states the articles used in the creation were
peer-reviewed.

X

9. The strengths and limitations of the body of evidence are
clearly described.
Comment:
No analysis of the body of evidence was included in the
presentation of the guidelines.

X

10. The methods for formulating the recommendations are
clearly described.
Comment:
No analysis of the methods for formulating the
recommendations was included.

X

11. The health benefits, side effects and risks have been
considered in formulating the recommendations.
Comment:
Side effects and common complications related to the
treatment are identified.

X

12. There is an explicit link between the recommendations and
the supporting evidence.
Comment:

X

7
Strongly
Agree
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AGREE II Rating
Domain

Item

1
Strongly
Disagree

2 3 4 5 6

The recommendations are correlated with references. The
strength of the evidence was not included as part of the
analysis.
13. The guideline has been externally reviewed by experts
prior to its publication.
Comment:
The guidelines were published in a peer-reviewed journal.

X

14. A procedure for updating the guideline is provided.
Comment:
No method for updating the recommendations was identified,
but the guideline itself is an update of a previous guideline.
Clarity of
presentation

Applicability

X

15. The recommendations are specific and unambiguous.
Comment:
The paper gives very specific recommendations regarding
diagnosis, dosing, and treatment.

X

16. The different options for management of the condition or
health issue are clearly presented.
Comment:
The paper acknowledges areas where the evidence is unclear.
It provides recommendations for when these treatments may
be appropriate and when they would not.

X

17. Key recommendations are easily identifiable.
Comment:
The recommendations are outlined on an easy to understand
flowsheet.

X

18. The guideline describes facilitators and barriers to its
application.
Comment:
No discussion of implementation was included in the
assessment.
19. The guideline provides advice and/or tools on how the
recommendations can be put into practice.
Comment:
No discussion or advice was discussed, but complications
regarding the guideline itself were discussed.

X

X

7
Strongly
Agree
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AGREE II Rating
Domain

Item

1
Strongly
Disagree

20. The potential resource implications of applying the
recommendations have been considered.
Comment:
There was no discussion of resource allocation.

2 3 4 5 6

X

21. The guideline presents monitoring and/ or auditing criteria.
Comment:
There was no discussion of monitoring of the guideline.

X

Editorial
22. The views of the funding body have not influenced the
independence
content of the guideline.
Comment:
The authors did not disclose any conflicts of interest. The
ADA is associated with the guideline but does not appear to be
a sponsor.

X

23. Competing interests of guideline development group
members have been recorded and addressed.
Comment:
The authors disclose no conflict of interest.
Overall
Guideline
Assessment

1. Rate the overall quality of this guideline.

Overall
Guideline
Assessment

2. I would recommend this guideline for use.
Notes:
The guideline is appropriate for use to treat DKA and HHS.
There are some weaknesses particularly related to the
methodology and the criteria used for making the
recommendations. There is also weakness related to the
strength of the recommendations. Nevertheless, the guideline
is well-referenced and any questions could be addressed by
further investigation of the provided references.

7
Strongly
Agree

X

3.83
Yes

Yes, with
modifications

Scope and
purpose

7

Stakeholder
involvement

3

Rigor of
development

2.9

No
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AGREE II Rating
Domain

Item

1
Strongly
Disagree

2 3 4 5 6

Clarity of
presentation

6

Applicability

1.5

Editorial
independence

5.5

7
Strongly
Agree
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Table 6 AGREE II assessment of the Diabetes Canada guidelines (Brouwers et al., 2010; Goguen
& Gilbert, 2010)
AGREE II Rating
Domain
Scope and
purpose

Stakeholder
involvement

Item

1
Strongly
Disagree

2 3 4 5 6

1. The overall objective(s) of the guideline is (are)
specifically described.
Comments:
The overall objectives are not identified as such, but
treatment of hyperglycemic emergencies is the clear overall
objective

7
Strongly
Agree

X

2. The health question(s) covered by the guideline is (are)
specifically described.
Comments:
Treatment of adults with DM who are having a
hyperglycemic emergency are clearly identified as the health
questions to be covered.

X

3. The population (patients, public, etc.) to whom the
guideline is meant to apply is specifically described.
Comment:
The guideline refers to adults with DM having
hyperglycemic emergencies and notes that pediatric
emergencies, while they have some similarities, have
differences. There is a separate guideline for pediatric
hyperglycemic emergencies.

X

4. The guideline development group includes individuals
from all the relevant professional groups.
Comment:
This is unclear from the paper. The authors of the guideline
are all MDs. No mention was made of any other
stakeholders.

X

5. The views and preferences of the target population
(patients, public, etc.) have been sought.
Comment:
No evidence was given of any assessment of end user needs.

X

6. The target users of the guideline are clearly defined.
Comment:
No evidence was given of any assessment of end user needs.

X
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AGREE II Rating
Domain
Rigor of
development

Item
7. Systematic methods were used to search for evidence.
Comment:
The paper contains no methods section outlining literature
searching strategies.

1
Strongly
Disagree

2 3 4 5 6
X

8. The criteria for selecting the evidence are clearly
described.
Comment:
The recommendations contain grades and levels of strength,
but the terms are not defined in this document. This
document is part of a larger collection of diabetes
recommendations. The definitions for these terms are
contained in the larger document.
9. The strengths and limitations of the body of evidence are
clearly described.
Comment:
No analysis of the body of evidence was included in the
presentation of the guidelines.

X

X

10. The methods for formulating the recommendations are
clearly described.
Comment:
The methods are not discussed in this document but are part
of the overall recommendations regarding diabetes care for
all Canadians.

X

11. The health benefits, side effects and risks have been
considered in formulating the recommendations.
Comment:
Side effects and common complications related to the
treatment are identified.

X

12. There is an explicit link between the recommendations
and the supporting evidence.
Comment:
The recommendations are correlated with references. The
strength of the evidence was not included as part of the
analysis.
13. The guideline has been externally reviewed by experts
prior to its publication.
Comment:

7
Strongly
Agree

X

X
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AGREE II Rating
Domain

Item

1
Strongly
Disagree

2 3 4 5 6

The guidelines were published in a peer-reviewed journal.
14. A procedure for updating the guideline is provided.
Comment:
No method for updating the recommendations was
identified, but the guideline itself is an update of a previous
guideline.
Clarity of
presentation

Applicability

X

15. The recommendations are specific and unambiguous.
Comment:
The paper gives very specific recommendations regarding
diagnosis, dosing, and treatment.

X

16. The different options for management of the condition
or health issue are clearly presented.
Comment:
The paper acknowledges areas where the evidence is
unclear. It provides recommendations for when these
treatments may be appropriate and when they would not.

X

17. Key recommendations are easily identifiable.
Comment:
The recommendations are outlined on an easy to understand
flowsheet.

X

18. The guideline describes facilitators and barriers to its
application.
Comment:
No discussion of implementation was included in the
assessment.

X

19. The guideline provides advice and/or tools on how the
recommendations can be put into practice.
Comment:
No discussion or advice was discussed, but complications
regarding the guideline itself were discussed.
20. The potential resource implications of applying the
recommendations have been considered.
Comment:
There was no discussion of resource allocation.
21. The guideline presents monitoring and/ or auditing
criteria.

X

X

X

7
Strongly
Agree
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AGREE II Rating
Domain

Item

1
Strongly
Disagree

2 3 4 5 6

7
Strongly
Agree

Comment:
Editorial
independence

22. The views of the funding body have not influenced the
content of the guideline.
Comment:
The authors disclose personal fees from pharmaceutical
companies. They state the fees were not related to this work.

X

23. Competing interests of guideline development group
members have been recorded and addressed.
Comment:
The authors disclose personal fees from pharmaceutical
companies. They state the fees were not related to this work
Overall
Guideline
Assessment

3. Rate the overall quality of this guideline.

Overall
Guideline
Assessment

4. I would recommend this guideline for use.
Notes:
The guideline is appropriate for use to treat DKA and HHS.
There are some weaknesses particularly related to the
methodology and the criteria used for making the
recommendations. This document is part of a larger
collection of diabetes recommendations for Canadians and
Canadian healthcare providers.

X

4.09
Yes

Yes, with
modifications

Scope and
purpose

6

Stakeholder
involvement

3

Rigor of
development

4

Clarity of
presentation

6

Applicability

1.5

Editorial
independence

5.5

No
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Table 7 Levels of evidence explained (Ackley, Swan, Ladwig, & Tucker, 2008, p. 7)
Level
Level I

Definition
Evidence from a systematic review or meta- analysis of all relevant RCTs (randomized controlled trial) or
evidence-based clinical practice guidelines based on systematic reviews of RCTs or three or more RCTs of
good quality that have similar results.

Level II

Evidence obtained from at least one well-designed RCT (e.g. large multi-site RCT).

Level III

Evidence obtained from well-designed controlled trials without randomization (i.e. quasi-experimental).

Level IV

Evidence from well-designed case-control or cohort studies.

Level V

Evidence from systematic reviews of descriptive and qualitative studies (meta-synthesis).

Level VI

Evidence from a single descriptive or qualitative study.

Level VII

Evidence from the opinion of authorities and/or reports of expert committees.”
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guideline for
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Annals of
Pharmacotherap
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https://doi.org/10
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/ Pubmed
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impact of an
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guideline and
order set for
hyperglycemic
emergencies” (p.
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hyperglycemic
emergency with
DKA or HHS at a
tertiary academic
medical center.
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Patients under 18
were excluded.

Retrospective prepost observational
chart review.
Adult patients
with ICD-9 code
for DKA or HHS
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Variables
measured
included hospital
LOS, ICU LOS,
and time to anion
gap closure.

No difference in
mean hospital
stay. ICU LOS
was shorter in
POST group (64.8
vs 37.1 hours, p <
.01) and shorter
time to anion gap
closure (13 hours
PRE vs 9.3 hours
POST, p < .01)

“Implementation
of an institutional
guideline and
order set for
hyperglycemic
emergencies
decreased ICU
LOS and time to
anion gap closure,
with no
differences in
rates of
hypoglycemia.”

Improved ICU
LOS and
anion gap
closure.
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2
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Douglas, I. S.,
Foster, M., &
Albert, R. K.
(2007).
Mandatory
protocol for
treating adult
patients with
diabetic
ketoacidosis
decreases
intensive care
unit and hospital
lengths of stay:
results of a
nonrandomized
trial. Critical
Care Medicine,
35(1), 41–47. /
found in review
of references

“To determine the
effect of a
mandatory
protocol for
treating diabetic
ketoacidosis” (p.
41).

“Universityaffiliated U.S.
public teaching
hospital.
Patients: A total
of 241
consecutive
nonpregnant
patients>18yrs old
admitted to a
medical intensive
care unit for
diabetic
ketoacidosis
between January
2000 and January
2005” (p. 41).

Retrospective prepost observational
chart review. Data
was collected
from the charts of
adult patients
treated for DKA.
Variables
measured include
hospital LOS,
ICU LOS, and
time to anion gap
closure.

“Before protocol
implementation,
the mean ICU and
hospital LOS
were 44 hrs and
91 hrs,
respectively. After
implementation,
ICU and hospital
LOS decreased to
34 hrs, p < .007.
and 64 hrs, p <
.007, respectively
Time to anion gap
closure also
decreased from
15.4 hrs to 10.3
hrs, p < .001.

Improvements in
ICU LOS and
decreased time to
anion gap closure.
No increase in
hypoglycemia
episodes

Reduced
hospital and
ICU LOS.
Reduced time
to anion gap
closure.

Level IV

59

No.

Citation /
Search Engine
Used

Purpose/
Objectives/
Description of
Intervention (if
appropriate)

Study
population/
Sample/
Setting

Study Design/
Methods/
Major Variables/
Instruments and
Measures

Result(s)/
Main Findings

Implications/
critique

Themes/
Comments

Level of
Evidence

3

Clark, A., Kraut,
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(2019).
Evaluation of a
diabetic
ketoacidosis
order set in
adults with type
1 and type 2
diabetes at a
tertiary academic
medical centre: A
retrospective
chart audit.
Canadian
Journal of
Diabetes, 43(5),
304.
doi:10.1016/j.jcjd
.2018.11.004 /
CINAHL and
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Examine safety
and efficacy of an
order set for
management of
DKA for patients
with diabetes.

Patients admitted
with DKA (in a
tertiary academic
medication center)
prior to
implementation of
a DKA order set
(n = 59) compared
to patients
admitted with
DKA after
implementation of
a DKA orders et
(n = 47). Study
examined a 4.5year period (2.25
years before and
after order set).

Retrospective prepost observational
chart review. Data
was collected
from the charts of
adult patients
admitted with
DKA. Patients
with HHS were
excluded.
Variables
measured include
hospital LOS and
time to anion gap
closure

Median length of
hospital stay for
order-set cohort:
3.53 days
compared to preorder-set cohort:
4.6 days, p = .102.
Time to anion gap
closure was 4.0
hrs for the order
set group and 5.2
hrs for the pre
order set group, p
= .09.

No statistically
significant
difference
between the two
groups, but both
groups were
small.

Patients who
received the
order set were
in the hospital
for fewer days
and had
shorter time to
anion gap
closure, but
the difference
was not
statistically
significant.
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Evaluation of a
computerized
insulin dosing
tool for the
treatment of
diabetic
ketoacidosis.
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Pharmacy
Practice.
https://doi.org/10
.1177/089719001
9834367 /
Pubmed

Evaluation of
computerized
insulin dosing
tools (CIDT)
coupled with
diabetic
ketoacidosis
(DKA) order set.

Study was
conducted at
urban medical
center. Patients in
the study were
over 18 with a
primary diagnosis
of DKA (plasma
glucose > 250m
anion gap > 10,
and positive urine
and/or serum
ketones.
Insulin regimen
was either
provider managed
or managed by
CIDT and the
pharmacy.

Retrospective prepost observational
chart review. Data
was collected
from the charts of
adult patients
admitted with
DKA. Variables
measured include
ICU LOS and
time to anion gap
closure.

Time (hours) to
anion gap closure
pre group 12.5 hrs
and post group
10.7 hrs, p = .24.
ICU LOS 40.6 hrs
pre order set and
40.8 hrs post
order set, p =
0.84.

Improvement in
anion gap closure
but no difference
in ICU LOS.

No
statistically
significant
differences.
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Hara, J., Rahbar,
A., Jeffres, M., &
Izuora, K.
(2013). Impact of
a hyperglycemic
crises protocol.
Endocrine
Practice: Official
Journal of the
American
College of
Endocrinology
and the American
Association of
Clinical
Endocrinologists.
, 19(6), 953–962.
https://doi.org/10
.4158/EP13077.
OR / Reference
review

“Evaluate the
efficacy of an
adult
hyperglycemic
protocol based in
the 2009
American
Diabetes
Association
(ADA) consensus
statement” (p.
953)

“256 adult
patients met the
criteria for
diabetic
ketoacidosis
(DKA) or
hyperosmolar
hyperglycemic
state ... Protocol
efficacy was
evaluated by
assessing time to
resolution of DKA
or HHS, length of
stay (LOS) in the
intensive care unit
(ICU)” (p. 953).
Study took place
from 2/11-2/12.

Retrospective prepost observational
chart review. Data
was collected
from the charts of
patients admitted
with DKA or
HHS. Variables
measured include
time to DKA
resolution,
hospital LOS and
ICU LOS.

Protocol patients
had a 9.2 hour
decrease, 95% CI
[4.70, 13.70], p <
.001, in time to
DKA resolution.
ICU LOS
decreased from
78.65 hrs to 50.55
hrs in protocol
patients, 95% CI
28.10 [9.27,
46.94] p = .004,
and decrease in
hospital LOS 6.35
days to 4.32 days,
95% CI 2.04
[0.61, 3.46], p =
.005

“Implementation
of a
hyperglycemic
crises protocol
decreased times to
resolution of
DKA and HHS
without increasing
the rate of
hypoglycemia or
hypokalemia.”

Statistically
significant
improvements
in ICU LOS,
hospital LOS
and time to
anion gap
closure.
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Evaluating an
order set for
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quality outcomes
in diabetic
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Emergency
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doi:10.1097/TM
E.000000000000
0178 / CINHAL
and Pubmed

Determine if
“utilization of an
evidence-based
order set versus an
individualized
provider approach
for the treatment
and management
of DKA decreases
resolution time
and occurrences
of hypoglycemia
and improves
clinical outcomes”
(p. 59).

“The setting was a
Level II trauma
center/ED and/or
critical care unit
of a 500-bed acute
care academic
medical center”
(p. 62). Sample
was 150 nonpregnant adults
over the age of 19.
Data was
collected 2/166/16 and 8/1612/16.

Retrospective prepost observational
chart review. The
data was collected
from the charts of
adult, nonpregnant patients
admitted with
DKA. Variables
measured include
hospital LOS.

Total LOS order
set 5.21 days and
no order set 7.26
days, p = 12.42.

Trends indicate
benefit of order
set. Not
statistically
significant.

No
statistically
significant
differences
were
observed.
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Laliberte, B.,
Yeung, S. Y. A.,
& Gonzales, J. P.
(2017). Impact of
diabetic
ketoacidosis
management in
the medical
intensive care
unit after order
set
implementation.
International
Journal of
Pharmacy
Practice, 25(3),
238-243.
doi:10.1111/ijpp.
12346 / CINAHL
and Pubmed

“To determine the
rate of compliance
to the 2006 and
2009 ADA DKA
guidelines in the
medical intensive
care unit (MICU)
at a large
academic medical
center after the
implementation of
a computerized
DKA order set
and protocol” (p.
238).

Adult patients
with DKA
admitted to the
MICU. 115 total
patients. Study
took place from
7/10-11/14.

Retrospective prepost observational
chart review. Data
was collected
from the charts of
adults admitted to
the MICU with
DKA. Variables
measured include
time to DKA
resolution, ICU
LOS.

“Time to DKA
resolution was
decreased 11.1
hours pre and 9.0
hours post order
set, p = .04.
ICU LOS was
increased in the
order set group
39.8 hours pre and
47 hours post
order set (p =
0.09).

Has stats for time
to DKA
resolution.
Statistically
significant

ICU LOS was
increased but
difference was
not
statistically
significant.
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8

Maghrabi et al.,
2012 /Reference
review

“To determine the
efficacy of an
algorithm-based
protocol to
manage diabetic
ketoacidosis
(DKA)” (p. 842)

“There were 88
patients managed
1-year prior
(control group)
and 70 patients
managed one year
after (study group)
implementation of
the algorithmbased DKA
protocol.”

Retrospective prepost observational
chart review. Data
was collected
from the chards of
adult patients
admitted with
DKA Variables
measured include
time to DKA
resolution.

DKA resolution
time was
significantly
shorter (11.5
hours pre order set
versus 8.5 hours
post order set, p =
.008.”

“Our study
showed that
implementation of
an algorithmbased protocol
reduced the DKA
resolution time
and hypoglycemic
events without
compromising
electrolyte
imbalance and
was associated
with improved
clinical measures
of DKA
management” (p.
843).

Improvements
in DKA
resolution.
Hospital LOS
and ICU LOS
were not
analyzed.
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Mohamed, et al.,
2019 /CINAHL
and Pubmed

Development,
pilot, and
evaluation of a
“Standardized
DKA protocol
adapted into
preprinted order
sets for use in the
emergency
department and
the acute
monitoring area”
(p. 256).

Adults admitted
with DKA at a
tertiary care
multicampus
hospital (in
Canada). N=110.
Study data was
collected from
9/13-3/14 and
9/15-6/16.

Retrospective prepost observational
chart review. Data
was collected
from the charts of
adult patients
admitted with
DKA. Variables
measured include
time to anion gap
closure.

Time to anion gap
closure was
reduced from 10.5
hours pre order set
to 5.4 hours post
order set, p < 0.01

Supports the idea
of using an
established DKA
protocol.

Use of the
order set
reduced time
to anion gap
closure.
Hospital LOS
and ICU LOS
were not
analyzed.

Level IV
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Appendix B

The Iowa Model Revised: Evidence-Based
Practice to Promote Excellence in Health Care

= a decision point
DO NOT REPRODUCE WITHOUT PERMISSION

©University

of Iowa Hospitals and Clinics, Revised June 2015
To request permission to use or reproduce, go to
https://uihc.org/evidence-based-practice/

Figure 1 The Iowa Model (used/reprinted with permission from the University of Iowa Hospitals
and Clinics, copyright 2015)
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Appendix C
Diabetic Ketoacidosis Order Set (Bull et al., 2007)
Phase 1. Occurs in the emergency department.
Monitoring. Assess volume status by checking mentation, orthostatic blood pressure and
pulse (if possible and unless the patient has hypotension and/or tachycardia when supine), and by
urine output.
Insert two large-bore intravenous catheters.
STAT measurement of complete blood count, electrolytes, glucose, blood urea nitrogen,
creatinine, calcium, magnesium, phosphate.
STAT urine analysis.
Intravenous fluids. Infuse 2– 4 L of normal saline (NS) in first hour (reduced for patients
in congestive heart failure, those with end-stage liver or renal disease, those > 65 yrs of age, or
those with hypoxemia).
Potassium repletion. Normal renal function.
Table 9 Potassium administration
Blood K+, mEq/l

KCl Administration, mEq/L

>5

None

4-5

20 mEq IV

3-4

20 mEq IV + 20 mEq oral or enteral

<3

20 mEq IV + 40 mEq oral or enteral

Maximum dose of 20 mEq/hr in a minimum of 100-mL intravenous solution through a central
catheter using an infusion pump.
Decreased renal function: call physician (MD).
Insulin. Do not initiate until potassium is > 3.2 mEq/L or is being corrected.
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If blood glucose is 150 –300 mg/dL: 5 units regular insulin intravenously, then 3 units/hr.
If blood glucose is > 300 mg/dL: 10 units regular insulin intravenously, then 6 units/hr.
Phase 2. Occurs in the intensive care unit after completing phase 1
Monitoring. Measure blood glucose every hour x2, then every 2 hrs.
Measure blood ketones every 4 hrs until negative.
Measure blood chemistry every 4 hrs until anion gap is closed AND electrolytes have
normalized.
Urine analysis, complete blood count, chemistry panel, calcium, magnesium, phosphorus
if not sent from ED.
Measure arterial blood gases if serum bicarbonate is < 6 mEq/L.
Measure orthostatic blood pressure and pulse at arrival in intensive care unit (if possible
and unless the patient has hypotension and/or tachycardia when supine).
Volume resuscitation (through intravenous catheter 1). Volume assessment by MD
using level of mentation and orthostatic changes in vital signs (Note: patient MAY require
continued high-rate volume infusion)
NS, 500 mL/hr intravenously2 hrs, then 250 mL/hr8 hrs, then1⁄2NS at 125 mL/hr, or
NS, 250 mL/hr intravenously2 hrs, then 125 mL/hr8 hrs, then CALL MD for orders
Add 20 mEq KCl/L for first 2 L only (further KCl repletion per Table 9)
Other rate ___________ INDICATION: _____________
Insulin and glucose (through intravenous catheter 2). Note: 5% dextrose in H2O
(D5W) is initiated at blood sugar of < 350 mg/dl.
Once adequate volume resuscitation, MD may cap intravenous catheter 1 and change
from D5W/NS to D5/1⁄2 NS.
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Adjust insulin and D5W rates based on blood glucose and CURRENT insulin rate (see
Table 10).
Mix regular insulin as follows: 1 unit/mL (100 units/100 mL).
D5W must be “piggybacked” into insulin catheter (intravenous catheter 2) to avoid
iatrogenic hypoglycemia or hyperglycemia.
Once the patient is euvolemic, has a blood sugar between 90 and 140 mg/dL, and has
cleared their blood ketones, insulin should be administered subcutaneously, and intravenous
insulin should be discontinued 30 mins later.
Potassium repletion
Select one
Normal renal function. Replete potassium as follows:(Note: Do not give the additional 20
mEq intravenous KCl if already added to NS).
KCl: ___________
Replete phosphorus if < 1.5 mg/dL with two 500-mg tablets of potassium phosphate
neutral or 20 mmol potassium phosphate intravenously over 6 hrs if not taking orally. If
phosphorus is < 1.0 mg/dL, give a single dose of 0.24 mmol/kg.
Replete magnesium if < 1.5 with 2 g of magnesium sulfate intravenously.
Insulin and 5% dextrose in H2O (D5W) infusion.
Table 10 Insulin infusion rates
Glucose,
mg/dl
< 65
66-90

Current Insulin infusion rate
1-5 units/hr
6-10 units/hr 11-16
units/hr
Discontinue insulin, give 50% dextrose 25
ml IV push, measure blood glucose in 30
minutes
Decrease rate by 50%, measure blood
glucose in 1 hr

D5W rate,
ml/hr
250
225

If
hemodynamically
stable, may
change to D5 ½

70

91-140
141-200
201-250

251-300

301-350

351-400

> 401

No change

Decrease 2 units/hr if blood
glucose is falling
2 units IV push and increase No change
rate 1 unit/hr
2-unit IV
3-unit IV
4-unit IV
push
push
push increase
increase 1
increase 2
3 units/hr
unit/hr
units/hr
6-unit IV
8-unit IV
8-unit IV
push
push
push increase
increase 1
increase 2
3 units/hr
unit/hr
units/hr
8-unit IV
10-unit IV
10-unit IV
push
push
push increase
increase 1
increase 3
4 units/hr
unit/hr
units/hr
Endocrine
Consult
10-unit IV
12-unit IV
12-unit IV
push
push
push increase
increase 2
increase 4
6 units/hr
units/hr
units/hr
Endocrine
Consult
401Call MD for new orders Endocrine
Consult

200

normal saline and
cap IV catheter 1

175
150

100

50

-

-

Modifications. For severe chronic heart failure or end-stage renal disease: administer
10% of the above volume using D50W (e.g., if blood glucose is 91–140 mg/dL, give D50W at
20 mL/hr through a central catheter).
For other conditions requiring volume restriction (e.g., left ventricular diastolic
dysfunction, end-stage liver disease), give50% of volume using D10W (e.g., if blood glucose is
91–140 give D10W at 100 mL/hr)
Other orders: Call MD if pH < 6.9 for 2 hrs for consideration of sodium bicarbonate
drip.
Additional labs now:
Hemoglobin A1C
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Fasting lipids
Other
Morning labs:
Diet: increase diet as tolerated once nausea/vomiting have resolved
Other
Call MD for discontinuation of intravenous insulin protocol and initiation of
subcutaneous insulin once diabetic ketoacidosis and nausea/vomiting have resolved

